RhumbLine Advisers
LUNG icon

RhumbLine Advisers’s Pulmonx LUNG Stock Holding History

RhumbLine Advisers’s Portfolio LUNG Stock Details LUNG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.2K Sell
19,383
-26,997
-58% -$37.2K ﹤0.01% 3789
2026
Q1 		$59.8K Sell
46,380
-9,861
-18% -$16.3K ﹤0.01% 3561
2025
Q4 		$124K Sell
56,241
-2,904
-5% -$5.46K ﹤0.01% 3386
2025
Q3 		$95.8K Buy
59,145
+3,484
+6% +$7.29K ﹤0.01% 3534
2025
Q2 		$144K Sell
55,661
-297
-0.5% -$1.17K ﹤0.01% 3396
2025
Q1 		$377K Buy
55,958
+2,455
+5% +$17.4K ﹤0.01% 2761
2024
Q4 		$363K Buy
53,503
+2,488
+5% +$16.4K ﹤0.01% 2875
2024
Q3 		$423K Sell
51,015
-691
-1% -$5K ﹤0.01% 2814
2024
Q2 		$328K Sell
51,706
-936
-2% -$7.2K ﹤0.01% 2945
2024
Q1 		$488K Buy
52,642
+1,734
+3% +$20.3K ﹤0.01% 2680
2023
Q4 		$649K Buy
50,908
+1,977
+4% +$20.6K ﹤0.01% 2508
2023
Q3 		$505K Sell
48,931
-1,225
-2% -$14.2K ﹤0.01% 2607
2023
Q2 		$658K Buy
50,156
+4,866
+11% +$59.5K ﹤0.01% 2518
2023
Q1 		$506K Buy
45,290
+1,583
+4% +$15.6K ﹤0.01% 2428
2022
Q4 		$368K Buy
43,707
+1,364
+3% +$13K ﹤0.01% 2598
2022
Q3 		$705K Buy
42,343
+3,093
+8% +$57K ﹤0.01% 2335
2022
Q2 		$578K Buy
39,250
+12,549
+47% +$259K ﹤0.01% 2419
2022
Q1 		$662K Buy
26,701
+1,617
+6% +$41.8K ﹤0.01% 2293
2021
Q4 		$804K Sell
25,084
-506
-2% -$18.5K ﹤0.01% 2298
2021
Q3 		$921K Buy
25,590
+1,247
+5% +$49.1K ﹤0.01% 2261
2021
Q2 		$1.07M Buy
24,343
+11,788
+94% +$513K ﹤0.01% 2215
2021
Q1 		$574K Buy
12,555
+918
+8% +$52.7K ﹤0.01% 2425
2020
Q4 		$803K Buy
+11,637
New +$570K ﹤0.01% 2240

Other funds holding LUNG

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ECM
ExodusPoint Capital Management New York $15.5B AUM 38.81% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

RhumbLine Advisers's LUNG Position: Q2 2026 in Review

RhumbLine Advisers reduced its Pulmonx (LUNG) stake by 58% in Q2 2026, selling an estimated $37.2K and leaving 19,383 shares worth $25.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3789.

RhumbLine Advisers first reported a position in LUNG in Q4 2020 and has held it in 23 quarters since. The position peaked at $1.07M in Q2 2021. 108 funds tracked by Wall St. Rank hold LUNG as of Q2 2026.

  • RhumbLine Advisers held 19,383 shares of Pulmonx worth $25.2K as of Q2 2026.
  • RhumbLine Advisers sold 26,997 Pulmonx shares in Q2 2026, an estimated $37.2K.
  • Pulmonx made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3789 holding.
  • RhumbLine Advisers first reported a position in Pulmonx in Q4 2020 and has held it in 23 quarters since.
  • RhumbLine Advisers's Pulmonx position peaked at $1.07M in Q2 2021.
  • 108 funds tracked by Wall St. Rank held Pulmonx as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.